Pharmacological studies on the low molecular weight heparin derivative CY 216.
In animal experiments pharmacological properties of the low molecular weight heparin derivative CY 216 were determined. The heparin fragment studied caused concentration-dependent anticoagulant effects in vitro. Investigations in vivo demonstrated the antithrombotic potency of the drug in experimental models of venous and arterial thrombosis in rats. In dependence on the dose administered CY 216 reduced the formation of stasis-induced thrombi of the jugular vein and prevented the thrombotic occlusion of the carotid artery after electrically induced damage of the vessel wall. An influence on primary haemostasis measured by prolongation of bleeding time after standardized incision of the rat tail could only be observed at doses which were higher than that required for antithrombotic effects.
Kaiser
B
B
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
Kühnemuth
G
G
Markwardt
F
F
D000818:Animals; D000925:Anticoagulants; D004558:Electric Stimulation; D005260:Female; D005343:Fibrinolytic Agents; D006487:Hemostasis; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013924:Thrombophlebitis / Q000188:drug therapy / Q000503:physiopathology; D013927:Thrombosis / Q000188:drug therapy / Q000503:physiopathology
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight